HLA-DR Antibody (ML11C11): sc-73366

HLA-DR Antibody (ML11C11) is a mouse monoclonal IgG1 kappa light chain antibody, designed to target the HLA-DR protein, also known as human leukocyte antigen DR isotype. HLA-DR is a crucial component of the major histocompatibility complex (MHC) class II molecules, which play an essential role in the immune system by presenting antigenic peptides to CD4+ helper T cells, thereby facilitating immune response regulation and activation. Anti-HLA-DR antibody (ML11C11) is raised against non-Hodgkin lymphoma (NHL) cells of human origin, ensuring precise binding to HLA-DR expressed on both normal and neoplastic B lymphocytes. The ability of HLA-DR to present exogenous antigens makes it pivotal in immune surveillance and the initiation of adaptive immune responses, highlighting the importance of accurately detecting its expression in various research and clinical settings. HLA-DR monoclonal antibody (ML11C11) is validated for use in multiple applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM), providing versatility for diverse experimental protocols. Additionally, variations in HLA-DR expression and polymorphisms have been linked to autoimmune diseases and cancer, making anti-HLA-DR antibody (ML11C11) an invaluable tool for studying disease mechanisms and potential therapeutic targets. By facilitating detailed analysis of HLA-DR interactions and functions, HLA-DR (ML11C11) antibody supports advancements in immunological research, diagnostics, and the development of targeted therapies.

The preferred HLA-DR antibody is HLA-DR Antibody (L243): sc-18875.